Activity of gatifloxacin tested against isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (North America, 1998-2003)

Diagnostic Microbiology and Infectious Disease
Kelley A FedlerThomas R Fritsche

Abstract

The SENTRY Antimicrobial Surveillance Program has monitored the activity of antimicrobial agents worldwide since 1997. The increasing number of clinical failures with established anti-infectives (penicillins, other beta-lactams, macrolides) among pediatric patients has stressed the importance for alternative therapeutic options. Ciprofloxacin has been recently approved for expanded use as treatment of complicated urinary tract infections in children, and gatifloxacin has been used successfully in clinical trials in selected children with severe or refractory otitis media. We evaluated the activity of gatifloxacin against strains isolated from children < 7 years of age and compared this to the general patient population (all ages included) using the SENTRY Program database. A total of 59826 North American isolates were collected, of which 4641 were from children (< 7 years old); all isolates were tested using reference broth microdilution methods. In contrast to the general population (GP), gatifloxacin resistance rates were very low among isolates from this younger patient group. Gatifloxacin susceptibility rates were > 84% for all pathogens evaluated in younger patients. All Streptococcus pneumoniae strains from children < 7 y...Continue Reading

References

Apr 1, 1994·The Journal of Antimicrobial Chemotherapy·J M Domagala
Dec 1, 1995·Antimicrobial Agents and Chemotherapy·M NakashimaH Uchida
Feb 12, 1998·Proceedings of the National Academy of Sciences of the United States of America·X ZhaoK Drlica
Jun 3, 1999·The Pediatric Infectious Disease Journal·U B Schaad
Jul 21, 1999·Human & Experimental Toxicology·T TakizawaK Owen
Apr 5, 2000·The Journal of Antimicrobial Chemotherapy·J Fung-TomcD Bonner
Sep 13, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D M Grasela
Feb 19, 2002·Antimicrobial Agents and Chemotherapy·Angela B BrueggemannGary V Doern
Aug 31, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lionel A MandellPatrice Courvalin
Dec 23, 2003·The Pediatric Infectious Disease Journal·Richard Grady
Jan 5, 2005·Diagnostic Microbiology and Infectious Disease·Sujata M BhavnaniPaul G Ambrose
Feb 25, 2005·Antimicrobial Agents and Chemotherapy·Edmund V CapparelliDennis M Grasela
Jul 20, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael E PichicheroRoger Echols
Sep 8, 2005·International Journal of Antimicrobial Agents·Pia WogeliusHenrik Toft Sørensen
Nov 17, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Roger EcholsMichael E Pichichero

❮ Previous
Next ❯

Citations

Jun 24, 2015·Journal of Chemotherapy·Caterina BacciElena Chiappini
Feb 13, 2016·Journal of Clinical Pharmacology·Karisma Patel, Jennifer L Goldman
Apr 11, 2018·The Pediatric Infectious Disease Journal·Itay Tokatly LatzerItai M Pessach
Dec 5, 2006·Expert Review of Anti-infective Therapy·Ioanna M Velissariou
Oct 11, 2012·Evidence-based Complementary and Alternative Medicine : ECAM·Zaleha ShafieiJalifah Latip
Mar 31, 2015·Conservation Biology : the Journal of the Society for Conservation Biology·David A Eads, Dean E Biggins
Aug 10, 2011·Anaesthesia and Intensive Care·G SideriM E Falagas
Nov 20, 2016·Journal of the Pediatric Infectious Diseases Society·Latania K LoganUNKNOWN Prevention Epicenters Program, US Centers for Disease Control and Prevention
Sep 29, 2011·Pediatrics·John S BradleyUNKNOWN American Academy of Pediatrics

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Roger EcholsMichael E Pichichero
The New England Journal of Medicine
Cynthia G WhitneyActive Bacterial Core Surveillance of the Emerging Infections Program Network
© 2021 Meta ULC. All rights reserved